‘Revolutionary’ drug for prostate cancer
| | | | |

‘Revolutionary’ drug for prostate cancer

Byangie vallejo

This article was taken from: https://www.bbc.co.uk/news/health-49877843 By BBC Health news Olaparib could become a revolutionary treatment for prostate cancer – the first genetically targeted drug for fighting the disease, say experts. The precision medicine is already used by the NHS for ovarian cancer and has been called a game-changer by cancer doctors. A cancer conference heard how,…

Advanced melanoma: Dual drugs increase survival of ‘untreatable’ cancer – study
| | | |

Advanced melanoma: Dual drugs increase survival of ‘untreatable’ cancer – study

Byangie vallejo

This article was taken from: https://news.sky.com/story/advanced-melanoma-dual-drugs-increase-survival-of-untreatable-cancer-study-11821530 By Sky News A decade ago, only one in 20 sufferers would survive for five years, with many living for just six to nine months. Patients with a skin cancer once thought untreatable can see their survival chances increase by 50% with a dual drug cocktail, a study indicates….

Cancer survival in the UK improving, but lagging behind – study
| | |

Cancer survival in the UK improving, but lagging behind – study

Byangie vallejo

This article was taken from: https://www.bbc.co.uk/news/health-49661516 By BBC Health News Cancer survival in the UK is on the up, but is still lagging behind other high-income countries, analysis suggests. Five-year survival rates for rectal and colon cancer improved the most since 1995, and pancreatic cancer the least. Advances in treatment and surgery are thought to…

‘Game-changing’ immunotherapy cancer drug boosts survival rates five-fold
| | | | |

‘Game-changing’ immunotherapy cancer drug boosts survival rates five-fold

Byangie vallejo

This article was taken from: https://www.telegraph.co.uk/news/2019/09/10/game-changing-immunotherapy-cancer-drug-boosts-survival-rates/ By Laura Donnelly, health editor An ew immunotherapy cancer drug boosts survival rate five-fold, scientists from Yale have found. Patients with advanced lung cancer were far more likely to be alive after five years, compared with those given standard chemotherapy. The immunotherapy drug nivolumab, which is used for several cancers, works…

Cancer ‘biggest middle-age killer in rich nations’
| | |

Cancer ‘biggest middle-age killer in rich nations’

Byangie vallejo

This article was taken from: https://www.bbc.co.uk/news/health-49558223 By BBC Health news Cancer now causes more deaths among the middle-aged in higher-income countries than cardiovascular disease, a study suggests. Globally, heart problems and stroke is the leading cause of death at this age. But the researchers say people in rich nations are 2.5 times more likely to…